197 related articles for article (PubMed ID: 11451550)
21. Use of intramuscular progesterone versus intravenous albumin for the prevention of ovarian hyperstimulation syndrome.
Costabile L; Unfer V; Manna C; Gerli S; Rossetti D; Di Renzo GC
Gynecol Obstet Invest; 2000; 50(3):182-5. PubMed ID: 11014951
[TBL] [Abstract][Full Text] [Related]
22. Daily low-dose hCG stimulation during the luteal phase combined with GnRHa triggered IVF cycles without exogenous progesterone: a proof of concept trial.
Andersen CY; Elbaek HO; Alsbjerg B; Laursen RJ; Povlsen BB; Thomsen L; Humaidan P
Hum Reprod; 2015 Oct; 30(10):2387-95. PubMed ID: 26209535
[TBL] [Abstract][Full Text] [Related]
23. Low dose human chorionic gonadotropin administration at the time of gonadotropin releasing-hormone agonist trigger versus 35 h later in women at high risk of developing ovarian hyperstimulation syndrome - a prospective randomized double-blind clinical trial.
Engmann LL; Maslow BS; Kaye LA; Griffin DW; DiLuigi AJ; Schmidt DW; Grow DR; Nulsen JC; Benadiva CA
J Ovarian Res; 2019 Jan; 12(1):8. PubMed ID: 30684970
[TBL] [Abstract][Full Text] [Related]
24. A gonadotropin releasing hormone agonist trigger of ovulation with aggressive luteal phase support for patients at risk of ovarian hyperstimulation syndrome undergoing controlled ovarian hyperstimulation.
Liang IT; Huang HY; Wu HM; Wang HS; Yu HT; Huang SY; Chang CL; Soong YK
Taiwan J Obstet Gynecol; 2015 Oct; 54(5):583-7. PubMed ID: 26522115
[TBL] [Abstract][Full Text] [Related]
25. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.
Engmann L; DiLuigi A; Schmidt D; Nulsen J; Maier D; Benadiva C
Fertil Steril; 2008 Jan; 89(1):84-91. PubMed ID: 17462639
[TBL] [Abstract][Full Text] [Related]
26. Can steroidal ovarian suppression during the luteal phase after oocyte retrieval reduce the risk of severe OHSS?
Wang YQ; Luo J; Xu WM; Xie QZ; Yan WJ; Wu GX; Yang J
J Ovarian Res; 2015 Sep; 8():63. PubMed ID: 26400057
[TBL] [Abstract][Full Text] [Related]
27. Does withholding gonadotrophin administration prevent severe ovarian hyperstimulation syndrome?
Lee C; Tummon I; Martin J; Nisker J; Power S; Tekpetey F
Hum Reprod; 1998 May; 13(5):1157-8. PubMed ID: 9647538
[TBL] [Abstract][Full Text] [Related]
28. Prevention of severe ovarian hyperstimulation syndrome in IVF with or without ICSI and embryo transfer: a modified 'coasting' strategy based on ultrasound for identification of high-risk patients.
Al-Shawaf T; Zosmer A; Hussain S; Tozer A; Panay N; Wilson C; Lower AM; Grudzinskas JG
Hum Reprod; 2001 Jan; 16(1):24-30. PubMed ID: 11139531
[TBL] [Abstract][Full Text] [Related]
29. Intravenous albumin does not prevent the development of severe ovarian hyperstimulation syndrome.
Chen CD; Wu MY; Yang JH; Chen SU; Ho HN; Yang YS
Fertil Steril; 1997 Aug; 68(2):287-91. PubMed ID: 9240258
[TBL] [Abstract][Full Text] [Related]
30. Intravenous albumin for the prevention of severe ovarian hyperstimulation syndrome in an in vitro fertilization program: a prospective, randomized, placebo-controlled study.
Shoham Z; Weissman A; Barash A; Borenstein R; Schachter M; Insler V
Fertil Steril; 1994 Jul; 62(1):137-42. PubMed ID: 8005278
[TBL] [Abstract][Full Text] [Related]
31. A simplified universal approach to COH protocol for IVF: ultrashort flare GnRH-agonist/GnRH-antagonist protocol with tailored mode and timing of final follicular maturation.
Orvieto R
J Ovarian Res; 2015 Nov; 8():69. PubMed ID: 26536862
[TBL] [Abstract][Full Text] [Related]
32. Intravenous albumin prevents moderate-severe ovarian hyperstimulation in in-vitro fertilization patients: a prospective, randomized and controlled study.
Isik AZ; Gokmen O; Zeyneloglu HB; Kara S; Keles G; Gulekli B
Eur J Obstet Gynecol Reprod Biol; 1996 Dec; 70(2):179-83. PubMed ID: 9119100
[TBL] [Abstract][Full Text] [Related]
33. [Relationship between letrozole administration during the luteal phase after oocyte retrieval and the early-stage ovarian hyperstimulation syndrome oocurrence].
He Q; Xu J; Cui S; Li H; Zhang C
Zhonghua Fu Chan Ke Za Zhi; 2014 Dec; 49(12):909-13. PubMed ID: 25608991
[TBL] [Abstract][Full Text] [Related]
34. [GnRH agonist triggering in IVF and luteal phase support in women at risk of ovarian hyperstimulation syndrome].
Guivarc'h-Levêque A; Jaffré F; Homer L; Moy L; Priou G; Colleu D; Denis I; Arvis P
Gynecol Obstet Fertil; 2013 Sep; 41(9):511-4. PubMed ID: 23972925
[TBL] [Abstract][Full Text] [Related]
35. Unilateral follicular aspiration and in-vitro maturation before contralateral oocyte retrieval: a method to prevent ovarian hyperstimulation syndrome.
Schröder AK; Schöpper B; Al-Hasani S; Diedrich K; Ludwig M
Eur J Obstet Gynecol Reprod Biol; 2003 Oct; 110(2):186-9. PubMed ID: 12969581
[TBL] [Abstract][Full Text] [Related]
36. Embryo freezing for preventing Ovarian Hyperstimulation Syndrome.
D'Angelo A; Amso N
Cochrane Database Syst Rev; 2002; (2):CD002806. PubMed ID: 12076453
[TBL] [Abstract][Full Text] [Related]
37. Timed unilateral ovarian follicular aspiration prior to administration of human chorionic gonadotrophin for the prevention of severe ovarian hyperstimulation syndrome in in-vitro fertilization: a prospective randomized study.
Egbase PE; Makhseed M; Al Sharhan M; Grudzinskas JG
Hum Reprod; 1997 Dec; 12(12):2603-6. PubMed ID: 9455821
[TBL] [Abstract][Full Text] [Related]
38. Comparison of intravenous albumin and transfer of fresh embryos with cryopreservation of all embryos for subsequent transfer in prevention of ovarian hyperstimulation syndrome.
Shaker AG; Zosmer A; Dean N; Bekir JS; Jacobs HS; Tan SL
Fertil Steril; 1996 May; 65(5):992-6. PubMed ID: 8612863
[TBL] [Abstract][Full Text] [Related]
39. [Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation].
Ye H; Huang GN; Cao YX; Zhong Y; Huang YH; Zhu GJ; Zhou LM; Chen ZJ; Shi JZ; Zeng Y; Weng N; Huang XF; Yang J; Zhu YM; Li YP; Yi D; Zhuang GL
Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):838-42. PubMed ID: 24444561
[TBL] [Abstract][Full Text] [Related]
40. Gonadotropin-releasing hormone antagonist versus agonist administration in women undergoing controlled ovarian hyperstimulation: cycle performance and in vitro steroidogenesis of granulosa-lutein cells.
Minaretzis D; Alper MM; Oskowitz SP; Lobel SM; Mortola JF; Pavlou SN
Am J Obstet Gynecol; 1995 May; 172(5):1518-25. PubMed ID: 7755066
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
